Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential new treatment option for patientsVision improvements were seen in both ...
Parnassus Mid Cap Growth Fund (Investor Shares) returned 7.90% (net of fees) for the quarter, outperforming the Russell Midcap Growth Index’s 2.78% return. Read more here.
Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential ...
Gilead Sciences, Inc. (Nasdaq: GILD) today shared positive data from the Phase 3 ASCENT-03 study demonstrating a highly statistically significant and clinically meaningful improvement in ...
Harbaji, W. and Abdulai, A. (2025) Factors Influencing Schoolchildren’s Obesity: A Qualitative Document Analysis of ...
4d
High-grade copper and gold intersections extend known mineralisation at FireFly’s Green Bay by 650m
The furthest intersection returns 49m at 6.1% CuEq1 and remains open at depth; These results will form part of the Mineral Resource Estimate update set for this quarterKEY POINTS Drilling from the end ...
The authors describe an interesting approach to studying the dynamics and function of membrane proteins in different lipid environments. The important findings have theoretical and practical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback